The role of inhibition of aldose reductase in cancer management was investigated and proven through inhibition of aldose reductase-mediated ROS signaling and preventing activation of various oncogenic kinases and transcription factors that are responsible for the production of several carcinogenic mediators [17, 18]. Here, AKR1B1 is linked to cancer.